Alpha 1-antitrypsin deficiency surgery: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) No edit summary |
No edit summary |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Alpha 1-antitrypsin deficiency}} | {{Alpha 1-antitrypsin deficiency}} | ||
{{CMG}}; {{AE}}{{Mazia}} | {{CMG}}; {{AE}}{{Mazia}} | ||
==Overview== | ==Overview== | ||
[[Lung]] [[transplantation]] may be recommended for some [[patients]] with end-stage [[lung]] [[disease]]. Alpha 1-antitrypsin deficiency accounts for about 5% of all [[lung]] [[transplantation]] performed in the United States. Five year survival rates following [[lung]] [[transplant]] is approximately 50%. The rate of [[FEV1]] decline among AATD [[patients]] who received double [[lung]] [[transplantation]] was faster than among single [[lung]] recipients. The estimated median survival time was 11 years in [[transplant]] recipients versus 5 years in [[Control|controls]]. [[Lung volume reduction surgery|Lung volume reduction surgery (LVRS)]] can help relieve [[dyspnea]] and improve [[exercise capacity]] in [[patients]] with [[emphysema]]. Data regarding the [[efficacy]] of [[Lung volume reduction surgery|LVRS]] for individuals with AATD is limited and generally less favorable in magnitude and duration of [[FEV1]] improvement. | |||
===Lung Transplantation=== | ===Lung Transplantation=== | ||
*Lung transplantation may be recommended for some patients with end-stage lung disease. | *[[Lung transplantation]] may be recommended for some patients with [[Lung disease|end-stage lung disease]].<ref name="pmid14621095">{{cite journal |vauthors=Glanville AR, Estenne M |title=Indications, patient selection and timing of referral for lung transplantation |journal=Eur. Respir. J. |volume=22 |issue=5 |pages=845–52 |year=2003 |pmid=14621095 |doi= |url=}}</ref><ref name="pmid19949142">{{cite journal |vauthors=Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, Lesèche G, Porcher R, Mal H |title=Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis |journal=Ann. Intern. Med. |volume=151 |issue=11 |pages=767–74 |year=2009 |pmid=19949142 |doi=10.7326/0003-4819-151-11-200912010-00004 |url=}}</ref> | ||
*Alpha 1-antitrypsin deficiency accounts for about 5% of all lung transplantations performed in the United States. | *Alpha 1-antitrypsin deficiency accounts for about 5% of all [[Lung transplantation|lung transplantations]] performed in the United States. | ||
*Single lung transplant is more common despite the fact that outcome is better in patient who receive double lung transplant due to limitations on availability. | *Single [[lung]] [[transplant]] is more common despite the fact that outcome is better in patient who receive double [[lung]] [[transplant]] due to limitations on availability. | ||
*Five year survival rates following lung transplant is approximately 50%. | *Five year survival rates following [[lung]] [[transplant]] is approximately 50%. | ||
*Bronchiolitis obliterans being the major cause of death post-transplant. | *[[Bronchiolitis obliterans]] being the major cause of death post-transplant. | ||
*Outcomes of lung transplantation can vary considerably. | *Outcomes of [[lung transplantation]] can vary considerably. | ||
*For example, reports from Washington University Medical Center in St. Louis, the Copenhagen National Lung Transplant Group, and Zurich University Hospital reported no difference in 5-year survival rates between AATD-COPD and usual COPD recipients. | *For example, reports from Washington University Medical Center in St. Louis, the Copenhagen National Lung Transplant Group, and Zurich University Hospital reported no difference in 5-year survival rates between AATD-COPD and usual COPD recipients. | ||
*In contrast, the Toronto group reported that AATD patients had lower 10-year survival (23% vs 43%) compared with usual COPD patients. | *In contrast, the Toronto group reported that AATD patients had lower 10-year survival (23% vs 43%) compared with usual COPD patients. | ||
*A recent study from the 2 national lung transplantation centers in Sweden documented a median survival time for AATD-COPD patients of 12 years compared with only 6 years for usual COPD patients. | *A recent study from the 2 national lung transplantation centers in Sweden documented a median survival time for AATD-COPD patients of 12 years compared with only 6 years for usual COPD patients. | ||
*The rate of FEV1 decline among AATD patients who received double lung transplantation was faster than among single lung recipients. | *The rate of FEV1 decline among AATD patients who received double lung transplantation was faster than among single lung recipients. | ||
*This difference persisted after adjustment for age, smoking status, body mass index, oxygen use, exercise capacity, donor age, cytomegalovirus mismatch, and transplant type. | *This difference persisted after adjustment for [[age]], [[smoking]] status, [[body mass index]], [[Oxygen|oxygen use]], [[exercise capacity]], [[Donor|donor age]], [[cytomegalovirus]] mismatch, and [[Transplant|transplant type]]. | ||
*The estimated median survival time was 11 years in transplant recipients versus 5 years in controls. | *The estimated median survival time was 11 years in [[Transplant|transplant recipients]] versus 5 years in [[Control|controls]]. | ||
===Lung Volume Reduction Surgery=== | ===Lung Volume Reduction Surgery=== | ||
*Lung volume reduction surgery (LVRS) can help relieve dyspnea and improve exercise capacity in patients with emphysema. Data regarding the efficacy of LVRS for individuals with AATD is limited and generally less favorable in magnitude and duration of FEV1 improvement. | *[[Lung volume reduction surgery|Lung volume reduction surgery (LVRS)]] can help relieve [[dyspnea]] and improve [[exercise capacity]] in patients with [[emphysema]]. Data regarding the efficacy of [[Lung volume reduction surgery|LVRS]] for individuals with AATD is limited and generally less favorable in magnitude and duration of FEV1 improvement. | ||
*One study demonstrated that bilateral LVRS in AAT-deficient patients with emphysema can be beneficial but functional measurements except 6 min walk test, returned to baseline at 6–12 months. Although, LVRS was not recommended for management of AAT deficiency. | *One study demonstrated that [[Lung volume reduction surgery|bilateral LVRS]] in AAT-deficient patients with emphysema can be beneficial but functional measurements except 6 min walk test, returned to baseline at 6–12 months. Although, [[LVRS]] was not recommended for management of AAT deficiency. | ||
==References== | ==References== | ||
Latest revision as of 18:02, 22 January 2018
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency surgery On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency surgery |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Lung transplantation may be recommended for some patients with end-stage lung disease. Alpha 1-antitrypsin deficiency accounts for about 5% of all lung transplantation performed in the United States. Five year survival rates following lung transplant is approximately 50%. The rate of FEV1 decline among AATD patients who received double lung transplantation was faster than among single lung recipients. The estimated median survival time was 11 years in transplant recipients versus 5 years in controls. Lung volume reduction surgery (LVRS) can help relieve dyspnea and improve exercise capacity in patients with emphysema. Data regarding the efficacy of LVRS for individuals with AATD is limited and generally less favorable in magnitude and duration of FEV1 improvement.
Lung Transplantation
- Lung transplantation may be recommended for some patients with end-stage lung disease.[1][2]
- Alpha 1-antitrypsin deficiency accounts for about 5% of all lung transplantations performed in the United States.
- Single lung transplant is more common despite the fact that outcome is better in patient who receive double lung transplant due to limitations on availability.
- Five year survival rates following lung transplant is approximately 50%.
- Bronchiolitis obliterans being the major cause of death post-transplant.
- Outcomes of lung transplantation can vary considerably.
- For example, reports from Washington University Medical Center in St. Louis, the Copenhagen National Lung Transplant Group, and Zurich University Hospital reported no difference in 5-year survival rates between AATD-COPD and usual COPD recipients.
- In contrast, the Toronto group reported that AATD patients had lower 10-year survival (23% vs 43%) compared with usual COPD patients.
- A recent study from the 2 national lung transplantation centers in Sweden documented a median survival time for AATD-COPD patients of 12 years compared with only 6 years for usual COPD patients.
- The rate of FEV1 decline among AATD patients who received double lung transplantation was faster than among single lung recipients.
- This difference persisted after adjustment for age, smoking status, body mass index, oxygen use, exercise capacity, donor age, cytomegalovirus mismatch, and transplant type.
- The estimated median survival time was 11 years in transplant recipients versus 5 years in controls.
Lung Volume Reduction Surgery
- Lung volume reduction surgery (LVRS) can help relieve dyspnea and improve exercise capacity in patients with emphysema. Data regarding the efficacy of LVRS for individuals with AATD is limited and generally less favorable in magnitude and duration of FEV1 improvement.
- One study demonstrated that bilateral LVRS in AAT-deficient patients with emphysema can be beneficial but functional measurements except 6 min walk test, returned to baseline at 6–12 months. Although, LVRS was not recommended for management of AAT deficiency.
References
- ↑ Glanville AR, Estenne M (2003). "Indications, patient selection and timing of referral for lung transplantation". Eur. Respir. J. 22 (5): 845–52. PMID 14621095.
- ↑ Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, Lesèche G, Porcher R, Mal H (2009). "Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis". Ann. Intern. Med. 151 (11): 767–74. doi:10.7326/0003-4819-151-11-200912010-00004. PMID 19949142.